PMC:7102556 / 19318-19664
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 357 | 159-167 | Species | denotes | SARS-CoV | Tax:694009 |
| 358 | 168-176 | Species | denotes | patients | Tax:9606 |
| 359 | 272-280 | Species | denotes | patients | Tax:9606 |
| 360 | 328-336 | Species | denotes | MERS-CoV | Tax:1335626 |
| 361 | 337-345 | Species | denotes | patients | Tax:9606 |
| 370 | 116-125 | Chemical | denotes | ribavirin | MESH:D012254 |
| 371 | 192-211 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
| 372 | 217-226 | Chemical | denotes | ribavirin | MESH:D012254 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T72 | 159-167 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T73 | 267-271 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T208 | 22-30 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T131 | 12-21 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T132 | 116-125 | Chemical | denotes | ribavirin | http://purl.obolibrary.org/obo/CHEBI_63580 |
| T133 | 192-211 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
| T134 | 192-201 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T135 | 202-211 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T136 | 217-226 | Chemical | denotes | ribavirin | http://purl.obolibrary.org/obo/CHEBI_63580 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T123 | 0-346 | Sentence | denotes | Despite the antiviral activity observed with in vitro studies, the clinical effect was not consistent [75], in that ribavirin does not prolong the survival of SARS-CoV patients [74,76], while lopinavir/ritonavir plus ribavirin seemed to improve clinical outcomes for SARS patients [77], but the improvement was not confirmed in MERS-CoV patients. |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32017984-25278221-69697785 | 178-180 | 25278221 | denotes | 74 |
| 32017984-26228937-69697786 | 181-183 | 26228937 | denotes | 76 |
| 32017984-14985565-69697787 | 282-284 | 14985565 | denotes | 77 |